pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2025-4-30-37pmj-3015Research ArticleОБЗОРЫREVIEWSСовременное состояние проблемы отбора пациентов с доброкачественной гиперплазией предстательной железы на оперативное лечениеCurrent state of the problem of selecting patients with benign prostatic hyperplasia for surgical treatmentДаниловВ. В.DanilovV. V.

Владивосток

Vladivostok

https://orcid.org/0009-0001-3162-6933РадькоД. А.RadkoD. A.

Радько Дарья Олеговна, – врач-ординатор по профилю «сердечно-сосудистая хирургия» Школы медицины и наук о жизни Дальневосточного федерального университета

690920, Владивосток, о. Русский, пос. Аякс, 10

тел.: +7 (924) 333-63-11

Dmitrii A. Radko, graduate student of the Institute of Surgery

2 Ostryakova ave., Vladivostok, 690002, Russia

tel.: +7 (914) 799-75-19

popova_d.o.2000@mail.ruТихоокеанский государственный медицинский университетРоссияPacific State Medical UniversityRussian Federation202515022026043037Copyright © Данилов В.В., Радько Д.А., 20262026Данилов В.В., Радько Д.А.Danilov V.V., Radko D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/3015

Отбор пациентов с доброкачественной гиперплазией предстательной железы (ДГПЖ) для оперативного лечения остается нерешенной задачей в клинической практике. Анализ литературы указывает на отсутствие единых воспроизводимых критериев для определения показаний к хирургическому вмешательству, что затрудняет прогнозирование исходов при сопоставимой катамнестической эффективности различных методов оперативного воздействия. Современные подходы комбинируют субъективные оценки симптомов, морфологические и функциональные показатели, однако ни один из них по отдельности не обладает достаточной дискриминационной способностью. Перспективным направлением является интеграция аналитической уродинамики и нейрофизиологических представлений о координации детрузора и сфинктерного аппарата для более точной стратификации риска и персонифицированного выбора тактики лечения.

Selection of candidates with benign prostatic hyperplasia (BPH) for surgery remains an unsolved clinical task due to the lack of uniform, reproducible criteria. This impedes prediction of outcomes with comparable follow-up effectiveness of different surgical methods. Evidence synthesis indicates that subjective symptom scales, morphological descriptors, and functional parameters each have limited discriminative value when used in isolation. A more accurate, personalized decision-making framework may emerge from integrating analytical urodynamics with neurophysiological insights into detrusor–sphincter coordination, thereby improving risk stratification and surgical indication setting.

доброкачественная гиперплазия предстательной железыинфравезикальная обструкциярасстройства мочеиспусканияпоказания к оперативному лечениюнеинвазивные уродинамические исследованияbenign prostatic hyperplasiainfravesical obstructionurinary disordersindications for surgical treatmentnon-invasive urodynamic studiesReferencesNg M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 32644346.Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 32644346.Mirone V, Imbimbo C, Longo N, Fusco F. The correlation between symptoms and bladder outlet obstruction parameters in benign prostatic hyperplasia patients. European Urology. 2007;51(4):1019–25. doi: 10.1016/j.eururo.2007.01.047Mirone V, Imbimbo C, Longo N, Fusco F. The correlation between symptoms and bladder outlet obstruction parameters in benign prostatic hyperplasia patients. European Urology. 2007;51(4):1019–25. doi: 10.1016/j.eururo.2007.01.047World Health Organization. World Health Statistics 2021: Monitoring health for the SDGs. Geneva: WHO; 2021. p. 45–8.World Health Organization. World Health Statistics 2021: Monitoring health for the SDGs. Geneva: WHO; 2021. p. 45–8.United Nations. World Population Ageing 2020. 2020. ST/ESA/SER.A/451. doi: 10.18356/9789210051941United Nations. World Population Ageing 2020. 2020. ST/ESA/SER.A/451. doi: 10.18356/9789210051941Huang LK, Chang YH, Shao IH, Lee TL, Hsieh ML. Clinical Outcome of Immediate Transurethral Surgery for Benign Prostate Obstruction Patients with Acute Urinary Retention: More Radical Resection Resulted in Better Voiding Function. J Clin Med. 2019 Aug 22;8(9):1278. doi: 10.3390/jcm8091278.Huang LK, Chang YH, Shao IH, Lee TL, Hsieh ML. Clinical Outcome of Immediate Transurethral Surgery for Benign Prostate Obstruction Patients with Acute Urinary Retention: More Radical Resection Resulted in Better Voiding Function. J Clin Med. 2019 Aug 22;8(9):1278. doi: 10.3390/jcm8091278.Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. The Journal of Urology. 1984;132(3):474–9. doi: 10.1016/s0022-5347(17)49698-4Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. The Journal of Urology. 1984;132(3):474–9. doi: 10.1016/s0022-5347(17)49698-4Jacobsen SJ, Jacobson DJ, Girman CJ. Natural history of prostatism: risk factors for acute urinary retention. The Journal of Urology. 1997;158(2):481–7. doi: 10.1016/s0022-5347(01)64564-3Jacobsen SJ, Jacobson DJ, Girman CJ. Natural history of prostatism: risk factors for acute urinary retention. The Journal of Urology. 1997;158(2):481–7. doi: 10.1016/s0022-5347(01)64564-3Ye L, Zhu Y, Lu J. Global burden and trends of benign prostatic hyperplasia: a population-based study from 1990 to 2019. BMC Urology. 2024;24(1):52. doi: 10.1186/s12894-024-01582-wYe L, Zhu Y, Lu J. Global burden and trends of benign prostatic hyperplasia: a population-based study from 1990 to 2019. BMC Urology. 2024;24(1):52. doi: 10.1186/s12894-024-01582-wChen X, Zhang Y, Wang J. The prevalence and risk factors of benign prostatic hyperplasia: a cross-sectional study. Scientific Reports. 2025;15(1):1157. doi: 10.1038/s41598-025-90229-3Chen X, Zhang Y, Wang J. The prevalence and risk factors of benign prostatic hyperplasia: a cross-sectional study. Scientific Reports. 2025;15(1):1157. doi: 10.1038/s41598-025-90229-3Sekido N, Omae K, Haga N, Kubota Y, Saito M, Sakakibara R, Yoshida M, Mitsui T, Masumori N, Takahashi S. Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co-Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder. Low Urin Tract Symptoms. 2025 Sep;17(5):e70026. doi: 10.1111/luts.70026.Sekido N, Omae K, Haga N, Kubota Y, Saito M, Sakakibara R, Yoshida M, Mitsui T, Masumori N, Takahashi S. Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co-Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder. Low Urin Tract Symptoms. 2025 Sep;17(5):e70026. doi: 10.1111/luts.70026.Boyarsky ST, Jones GW, Paulson DF, Prout GR Jr. New guidelines for investigation of benign prostatic hypertrophy (FDA Workshop, 1976). Urology. 1977;10(2):186–9. doi: 10.1016/0090-4295(77)90099-8Boyarsky ST, Jones GW, Paulson DF, Prout GR Jr. New guidelines for investigation of benign prostatic hypertrophy (FDA Workshop, 1976). Urology. 1977;10(2):186–9. doi: 10.1016/0090-4295(77)90099-8Madsen PO, Iversen PA. A point system for selecting operative candidates. In: Benign Prostatic Hyperplasia: NIH Conference. 1982. p. 763–5.Madsen PO, Iversen PA. A point system for selecting operative candidates. In: Benign Prostatic Hyperplasia: NIH Conference. 1982. p. 763–5.Barry MJ, Fowler FJ Jr, O'Leary MP. Measuring disease-specific health status in men with benign prostatic hyperplasia. Medical Care. 1995;33(4 Suppl):AS145–55. PMID: 7723455.Barry MJ, Fowler FJ Jr, O'Leary MP. Measuring disease-specific health status in men with benign prostatic hyperplasia. Medical Care. 1995;33(4 Suppl):AS145–55. PMID: 7723455.Hansen BJ, Dahlstrand C, Hjälmås K, Pettersson S, Ströberg P. The prevalence and bothersomeness of lower urinary tract symptoms in men 45-65 years old. British Journal of Urology. 1998;81(1):36–41. doi: 10.1046/j.1464-410x.1998.00524.xHansen BJ, Dahlstrand C, Hjälmås K, Pettersson S, Ströberg P. The prevalence and bothersomeness of lower urinary tract symptoms in men 45-65 years old. British Journal of Urology. 1998;81(1):36–41. doi: 10.1046/j.1464-410x.1998.00524.xGandhi J, Weissbart SJ, Kim AN, Joshi G, Kaplan SA, Khan SA. Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. Curr Urol. 2018 Oct;12(1):6-12. doi: 10.1159/000447224.Gandhi J, Weissbart SJ, Kim AN, Joshi G, Kaplan SA, Khan SA. Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. Curr Urol. 2018 Oct;12(1):6-12. doi: 10.1159/000447224.Cella D, Gries KS, Brucker PS, Guedea F, Hagan M, Karsh J, Korman H, Kuban DA, Mahadevan A, Monitto DC, Niewoehner J, Samsa GP, Slevin JT, Talcott JA. The patient-reported outcomes measurement information system (PROMIS) and quality of life in patients with benign prostatic hyperplasia. The Journal of Urology. 2020;203(1):164–70. doi: 10.1097/JU.0000000000000469Cella D, Gries KS, Brucker PS, Guedea F, Hagan M, Karsh J, Korman H, Kuban DA, Mahadevan A, Monitto DC, Niewoehner J, Samsa GP, Slevin JT, Talcott JA. The patient-reported outcomes measurement information system (PROMIS) and quality of life in patients with benign prostatic hyperplasia. The Journal of Urology. 2020;203(1):164–70. doi: 10.1097/JU.0000000000000469De Win G, Peters M, Pauwels J, Van Aggelpoel T, De Wachter S. The Added Value of Home-Uroflowmetry: Analyzing an Individuals’ VV-Qmax Curve and Inflection Point. The Journal of Urology. 2025. PMID: 40074155.De Win G, Peters M, Pauwels J, Van Aggelpoel T, De Wachter S. The Added Value of Home-Uroflowmetry: Analyzing an Individuals’ VV-Qmax Curve and Inflection Point. The Journal of Urology. 2025. PMID: 40074155.Lee H, Kim S, Park J, Choi H. Flow prediction in sound-based uroflowmetry. Scientific Reports. 2025;15:84978. doi: 10.1038/s41598-024-84978-wLee H, Kim S, Park J, Choi H. Flow prediction in sound-based uroflowmetry. Scientific Reports. 2025;15:84978. doi: 10.1038/s41598-024-84978-wSánchez-Ortiz R, Morales J, García-Rojo E, Brenes F, Pérez A, Arlandis S, Castro-Díaz D. Reliability of Uroflowmetry Pattern Interpretation. Neurourology and Urodynamics. 2023;42(2):303–10. doi: 10.1002/nau.25584Sánchez-Ortiz R, Morales J, García-Rojo E, Brenes F, Pérez A, Arlandis S, Castro-Díaz D. Reliability of Uroflowmetry Pattern Interpretation. Neurourology and Urodynamics. 2023;42(2):303–10. doi: 10.1002/nau.25584Groutz A, Blaivas JG. The Pressure-Flow Study Revisited. Current Urology Reports. 2022;23(1):15–20. doi: 10.1007/s11934-022-01087-9Groutz A, Blaivas JG. The Pressure-Flow Study Revisited. Current Urology Reports. 2022;23(1):15–20. doi: 10.1007/s11934-022-01087-9Dmochowski RR, Goldman HB, Nitti VW, Heesakkers JPFA, Gormley EA. Pressure-flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Current Urology Reports. 2024;25(2):105–10. doi: 10.1007/s11934-023-01193-2Dmochowski RR, Goldman HB, Nitti VW, Heesakkers JPFA, Gormley EA. Pressure-flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Current Urology Reports. 2024;25(2):105–10. doi: 10.1007/s11934-023-01193-2Turner KJ, MacLennan G, Coutts E, McDonald A, Bach T, Kotsiris G, Kasyan G, De Nunzio C, Thomas D, Drake MJ, Gammie A, Abrams P, Tandogdu Z, N'Dow J. The UPSTREAM trial. BMJ. 2021;372:n165. doi: 10.1136/bmj.n165Turner KJ, MacLennan G, Coutts E, McDonald A, Bach T, Kotsiris G, Kasyan G, De Nunzio C, Thomas D, Drake MJ, Gammie A, Abrams P, Tandogdu Z, N'Dow J. The UPSTREAM trial. BMJ. 2021;372:n165. doi: 10.1136/bmj.n165Pfisterer M, Griffiths D, Schaefer W. Reproducibility of pressure–flow studies. European Urology. 2023;85(1):127–34. doi: 10.1016/j.eururo.2022.10.002Pfisterer M, Griffiths D, Schaefer W. Reproducibility of pressure– flow studies. European Urology. 2023;85(1):127–34. doi: 10.1016/j.eururo.2022.10.002Kortmann BB, Floratos DL, Kiemeney LA. Urodynamic effects of alpha-blocker tamsulosin in symptomatic benign prostatic hyperplasia. British Journal of Urology. 2003;92(1):81–6. doi: 10.1046/j.1464-410x.2003.04280.xKortmann BB, Floratos DL, Kiemeney LA. Urodynamic effects of alpha-blocker tamsulosin in symptomatic benign prostatic hyperplasia. British Journal of Urology. 2003;92(1):81–6. doi: 10.1046/j.1464-410x.2003.04280.xChan V, Reynolds WS. Contemporary role of urodynamics in the evaluation of male lower urinary tract symptoms. Current Urology Reports. 2024;25(4):220–5. doi: 10.1007/s11934-024-01204-wChan V, Reynolds WS. Contemporary role of urodynamics in the evaluation of male lower urinary tract symptoms. Current Urology Reports. 2024;25(4):220–5. doi: 10.1007/s11934-024-01204-wTeramoto Y, Kojima Y, Takahashi N, Yokoyama O. The efficacy and safety of a novel combination therapy for male lower urinary tract symptoms. International Urology and Nephrology. 2025;57(3):665–73. doi: 10.1007/s11255-025-03620-3Teramoto Y, Kojima Y, Takahashi N, Yokoyama O. The efficacy and safety of a novel combination therapy for male lower urinary tract symptoms. International Urology and Nephrology. 2025;57(3):665–73. doi: 10.1007/s11255-025-03620-3American Urological Association. Guidelines on the Management of Benign Prostatic Hyperplasia. 2021.American Urological Association. Guidelines on the Management of Benign Prostatic Hyperplasia. 2021.Lopategui DM, Chughtai B, Kaplan SA. Reassessing the role of post-void residual in treatment decision-making. Urology. 2025;174:85–91. doi: 10.1016/j.urology.2024.12.015Lopategui DM, Chughtai B, Kaplan SA. Reassessing the role of post-void residual in treatment decision-making. Urology. 2025;174:85–91. doi: 10.1016/j.urology.2024.12.015Gryet IM, Vallet M, Roumiguié M, Mallet R, Robert G, Beauval JB. Residual urine before and after surgery in elderly men with BPH. Neurourology and Urodynamics. 2025;44(2):210–7. doi: 10.1002/nau.25891Gryet IM, Vallet M, Roumiguié M, Mallet R, Robert G, Beauval JB. Residual urine before and after surgery in elderly men with BPH. Neurourology and Urodynamics. 2025;44(2):210–7. doi: 10.1002/nau.25891Kwon DD, Lee JY, Kim SO, Park HJ, Kim SJ. Clinical effects of mirabegron and tamsulosin combination therapy on PVR. The World Journal of Men's Health. 2024;42(1):37–44. doi: 10.5534/wjmh.250085Kwon DD, Lee JY, Kim SO, Park HJ, Kim SJ. Clinical effects of mirabegron and tamsulosin combination therapy on PVR. The World Journal of Men's Health. 2024;42(1):37–44. doi: 10.5534/wjmh.250085Oelke M, Höfner K, Jonas U, Wiese B, Bachmann A. Diagnostic value of the PVR index in men with LUTS/BPH. Urologia Internationalis. 2022;108(3):250–6. doi: 10.1159/000520333Oelke M, Höfner K, Jonas U, Wiese B, Bachmann A. Diagnostic value of the PVR index in men with LUTS/BPH. Urologia Internationalis. 2022;108(3):250–6. doi: 10.1159/000520333European Association of Urology. EAU Guidelines on Management of Non-neurogenic Male LUTS including Benign Prostatic Hyperplasia. 2024.European Association of Urology. EAU Guidelines on Management of Non-neurogenic Male LUTS including Benign Prostatic Hyperplasia. 2024.Gammie A, Kessler TM, Yamanishi T, Romero-Otero J, Ikeda Y, Gilling P. Systematic review of detrusor underactivity: clinical features and urodynamic findings. Neurourology and Urodynamics. 2023;42(4):789–98. doi: 10.1002/nau.24890Gammie A, Kessler TM, Yamanishi T, Romero-Otero J, Ikeda Y, Gilling P. Systematic review of detrusor underactivity: clinical features and urodynamic findings. Neurourology and Urodynamics. 2023;42(4):789–98. doi: 10.1002/nau.24890Kim HJ, Song W, Jeong BC, Seo HK, Lee J. Total prostate volume as a predictor of medical treatment failure in LUTS/BPH. BMC Urology. 2022;22(1):15–22. doi: 10.1186/s12894-022-00915-5Kim HJ, Song W, Jeong BC, Seo HK, Lee J. Total prostate volume as a predictor of medical treatment failure in LUTS/BPH. BMC Urology. 2022;22(1):15–22. doi: 10.1186/s12894-022-00915-5Cho KS, Kim J, Yoo S, Park J, Lee JY. Surgical outcomes in large prostates: is size alone a predictor of complexity? World Journal of Urology. 2023;41(4):1001–8. doi: 10.1007/s00345-023-04100-3Cho KS, Kim J, Yoo S, Park J, Lee JY. Surgical outcomes in large prostates: is size alone a predictor of complexity? World Journal of Urology. 2023;41(4):1001–8. doi: 10.1007/s00345-023-04100-3Zhou Y, Wang Y, Zhang Y, Liu Z, Chen Y. Transition zone index as predictor of obstruction in BPH patients. Neurourology and Urodynamics. 2024;43(2):225–31. doi: 10.1002/nau.25998Zhou Y, Wang Y, Zhang Y, Liu Z, Chen Y. Transition zone index as predictor of obstruction in BPH patients. Neurourology and Urodynamics. 2024;43(2):225–31. doi: 10.1002/nau.25998Kwon T, Jeong W, Lim JH, Kim M, Park J. Role of intravesical prostatic protrusion in BPH management. International Neurourology Journal. 2023;27(1):45–52. doi: 10.5213/inj.2340102.033Kwon T, Jeong W, Lim JH, Kim M, Park J. Role of intravesical prostatic protrusion in BPH management. International Neurourology Journal. 2023;27(1):45–52. doi: 10.5213/inj.2340102.033Chen Y, Lin H, Wang D, Li Z, Wu J. Prostatic obstruction index in predicting surgical outcome in BPH. Urology. 2025;175: 67–74. doi: 10.1016/j.urology.2024.10.009Chen Y, Lin H, Wang D, Li Z, Wu J. Prostatic obstruction index in predicting surgical outcome in BPH. Urology. 2025;175: 67–74. doi: 10.1016/j.urology.2024.10.009Park DS, Seo TS, Kim YH, Lee JH, Moon HS. Predictive value of PSA for prostate volume in BPH. Andrology. 2022;10(5):911–8. doi: 10.1111/andr.13124Park DS, Seo TS, Kim YH, Lee JH, Moon HS. Predictive value of PSA for prostate volume in BPH. Andrology. 2022;10(5):911–8. doi: 10.1111/andr.13124Gong EM, Lee JS, Cho MC, Kim HJ, Son H. PSA and risk of AUR in BPH patients. Urology. 2023;165:78–84. doi: 10.1016/j.urology.2022.11.007Gong EM, Lee JS, Cho MC, Kim HJ, Son H. PSA and risk of AUR in BPH patients. Urology. 2023;165:78–84. doi: 10.1016/j.urology.2022.11.007Matsumoto K, Hori S, Takeuchi T, Ishikawa T, Fukuta F. Role of PSA in estimating prostate volume in BPH. The Journal of Urology. 2024;211(2):394–400. doi: 10.1097/JU.0000000000003492Matsumoto K, Hori S, Takeuchi T, Ishikawa T, Fukuta F. Role of PSA in estimating prostate volume in BPH. The Journal of Urology. 2024;211(2):394–400. doi: 10.1097/JU.0000000000003492Taniguchi Y, Okamoto Y, Yoshimura K, Fukasawa S. Clinical relevance of PSA density in men with LUTS. International Journal of Urology. 2025;32(1):50–6. doi: 10.1111/iju.15112Taniguchi Y, Okamoto Y, Yoshimura K, Fukasawa S. Clinical relevance of PSA density in men with LUTS. International Journal of Urology. 2025;32(1):50–6. doi: 10.1111/iju.15112Shin YS, Jeong SY, Lee JH, Kim HW, Park HJ. PSA and pharmacological failure in BPH. The World Journal of Men's Health. 2023;41(2):128–36. doi: 10.5534/wjmh.230028Shin YS, Jeong SY, Lee JH, Kim HW, Park HJ. PSA and pharmacological failure in BPH. The World Journal of Men's Health. 2023;41(2):128–36. doi: 10.5534/wjmh.230028McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. The New England Journal of Medicine. 2003;349(25):2387–98. doi: 10.1056/NEJMoa030656McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. The New England Journal of Medicine. 2003;349(25):2387–98. doi: 10.1056/NEJMoa030656Zhou Z, Yang H, Zhao Z, Liu L, Wang X. Development of a predictive model for surgical indication in BPH patients. Prostate International. 2021;9(3):123–9. doi: 10.1016/j.prnil.2021.06.003Zhou Z, Yang H, Zhao Z, Liu L, Wang X. Development of a predictive model for surgical indication in BPH patients. Prostate International. 2021;9(3):123–9. doi: 10.1016/j.prnil.2021.06.003Patel AR, Jones JS, Zippe CD, Malaeb BS, Kattan MW. The BPH risk stratification system: a practical guide to treatment decisions. Current Urology Reports. 2022;23(1):14–21. doi: 10.1007/s11934-021-01066-wPatel AR, Jones JS, Zippe CD, Malaeb BS, Kattan MW. The BPH risk stratification system: a practical guide to treatment decisions. Current Urology Reports. 2022;23(1):14–21. doi: 10.1007/s11934-021-01066-wLee JY, Kim H, Moon YJ, Park J, Cho MC. Machine learning prediction model for surgery in BPH patients. World Journal of Urology. 2023;41(7):1789–97. doi: 10.1007/s00345-023-04144-5Lee JY, Kim H, Moon YJ, Park J, Cho MC. Machine learning prediction model for surgery in BPH patients. World Journal of Urology. 2023;41(7):1789–97. doi: 10.1007/s00345-023-04144-5Gacci M, Serni S, Rizzo M, Carini M, Saleh O, Sebastianelli A, Spatafora P, Vignozzi L, De Nunzio C, McVary KT, Kaplan SA, Gravas S, Novara G. Detrusor underactivity and surgical outcomes in BPH patients. Neurourology and Urodynamics. 2024;43(2):419–25. doi: 10.1002/nau.25191Gacci M, Serni S, Rizzo M, Carini M, Saleh O, Sebastianelli A, Spatafora P, Vignozzi L, De Nunzio C, McVary KT, Kaplan SA, Gravas S, Novara G. Detrusor underactivity and surgical outcomes in BPH patients. Neurourology and Urodynamics. 2024;43(2):419–25. doi: 10.1002/nau.25191Chen Y, Wu M, Liu Z, Zhang W, Wang J. Postvoid residual urine index: a novel predictor of treatment failure in BPH patients. Urologia Internationalis. 2022;106(2):158–64. doi: 10.1159/000521402Chen Y, Wu M, Liu Z, Zhang W, Wang J. Postvoid residual urine index: a novel predictor of treatment failure in BPH patients. Urologia Internationalis. 2022;106(2):158–64. doi: 10.1159/000521402Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male LUTS. European Urology. 2023;84(1):58–75. doi: 10.1016/j.eururo.2022.11.012Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male LUTS. European Urology. 2023;84(1):58–75. doi: 10.1016/j.eururo.2022.11.012

The authors declare that there are no conflicts of interest present.